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Abstract:	 		Long	Term	Efficacy	of	a	Supraciliary	Micro-Stent	Combined	with	Cataract	Surgery	in	the	Treatment	of	Glaucoma		
Purpose:	The	purpose	of	this	study	is	to	evaluate	the	long-term	efficacy	of	supraciliary	micro-stent	implantation	in	combination	with	phacoemulsification	in	the	treatment	of	mild-moderate	primary	open	angle	glaucoma	(POAG).	
Methods:	Retrospective	data	of	patients	previously	enrolled	in	the	“Study	of	an	Implantable	Device	for	Lowering	Intraocular	Pressure	in	Glaucoma	Patients	Undergoing	Cataract	Surgery”	(COMPASS	trial),	in	which	patients	with	mild-moderate	POAG	had	undergone	either	cataract	surgery	alone	or	cataract	surgery	combined	with	implantation	of	a	supraciliary	micro-stent,	were	collected.		Eligible	patients	had	since	exited	the	trial	and	had	5-8	years	of	postoperative	data	available.	The	primary	outcome	measure	was	the	proportion	of	eyes	with	a	“complete	success”	defined	as	an	IOP	≤	18	mmHg	on	no	glaucoma	medications	and	not	having	undergone	any	secondary	surgical	procedures	for	IOP	control.		Thirty-three	eyes	were	in	the	treatment	group	and	12	eyes	were	in	the	control	group.		Device	safety	was	also	reviewed.				
Results:	Significantly	more	eyes	in	the	treatment	group	achieved	a	“complete	success”	(61%)	versus	those	eyes	in	the	control	group	(17%)	(p<0.05).		When	controlling	for	patient	age,	sex,	preoperative	visual	field,	preoperative	IOP,	and	preoperative	anti-glaucoma	medication	usage,	eyes	in	the	treatment	groups	were	9	times	more	likely	to	meet	the	primary	outcome	measure	versus	control	group	(p=0.004).		Mean	postoperative	IOP	was	17.7	±	4.8	in	the	control	group	versus	15.0	±	4.4	in	the	treatment	group	(p=0.08),	while	mean	medication	usage	was	0.9	±	0.7	in	the	control	group	versus	0.4	±	0.7	in	the	treatment	group	(p=0.01).		Average	follow	up	was	6.38	years.		No	device	related	adverse	events,	such	as	corneal	decompensation	occurred.			
Conclusion:	Implantation	of	a	supraciliary	micro-stent	combined	with	cataract	surgery	in	eyes	with	mild-moderate	POAG	demonstrates	better	long	term	IOP	control	than	those	eyes	undergoing	cataract	surgery	alone.		
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Introduction:		 Glaucoma	is	a	chronic	and	progressive	optic	neuropathy	that	remains	the	second	leading	cause	of	blindness	in	the	world.1	It	is	estimated	that	nearly	3%	of	all	individuals	aged	40-80	years	old	have	primary	open	angle	glaucoma	(POAG).2	Currently	the	only	method	of	treatment	is	lowering	intraocular	pressure	(IOP)	to	reduce	ganglion	cell	damage,	and	thus	prevent	vision	loss.		Topical	hypotensive	medications	are	the	first	line	of	treatment	and	have	been	shown	to	delay	progression	of	optic	nerve	damage.3	Despite	the	availability	of	multiple	drug	options,	IOP	control	can	still	be	challenging.	Compliance	with	medication	is	poor,4	and	may	create	ocular	surface	disease	and	tolerability	issues.5	Laser	trabeculoplasty	has	proven	to	be	both	a	good	first	line	and	adjunctive	treatment	in	the	management	of	glaucoma.6	While	considered	a	safe	option,	it’s	effect	may	not	persist	over	time	and	further	IOP	lowering	may	be	required.6	Traditional	incisional	surgical	options	such	as	trabeculectomy	(gold	standard)	and	tube	shunt	devices	have	excellent	IOP	lowering	capability,	but	are	associated	with	significant	ocular	morbidity	and	high	failure	rates.7	This	has	limited	their	use	to	those	patients	with	more	advanced	disease	in	which	other	methods	have	failed.8	Over	the	last	decade	there	has	been	a	push	toward	less	invasive	glaucoma	surgical	techniques	that	cause	as	little	trauma	as	possible	to	the	target	tissue	involved.9	Reproducible	techniques	that	are	not	only	efficacious,	but	also	effectively	lowering	IOP	and	the	medication	burden	are	of	interest	to	not	only	glaucoma	specialists,	but	to	all	practitioners	who	manage	glaucoma.	Micro-invasive	glaucoma	surgery	(MIGS)	is	an	attractive	option	as	it	provides	a	safer	and	less	invasive	method	for	IOP	lowering	while	enhancing	patient	comfort	and	recovery	time.10	Current	MIGS	devices	and	procedures	increase	aqueous	outflow	in	one	of	three	ways;	bypassing	the	trabecular	meshwork,	i.e.	iStent	(Glaukos,	San	Clemente,	California),	increasing	uveoscleral	outflow	via	the	suprachoroidal	space,	i.e.	CyPass	Micro-Stent	(Alcon	Laboratories,	Inc.,	Fort	Worth,	Texas),	or	creating	a	subconjunctival	conduit,	i.e.	XEN45	gel	stent	(Allergan	PLC,	Irvine,	California).	11	These	MIGS	procedures	may	represent	a	suitable	option	to	fill	the	therapeutic	gap	between	drug	therapy	and	traditional	incisional	glaucoma	surgeries.		 The	CyPass	Micro-Stent	is	implanted	in	the	supraciliary	space	and	provides	a	
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permanent	channel	through	which	aqueous	can	exit	the	anterior	chamber	through	the	suprachoroidal	space	thus	increasing	non-trabecular	flow.12	It	is	a	fenestrated	6.35	mm	long	stent	made	of	polyimide,	and	has	an	inner	lumen	of	300	microns.		Using	a	specialized	guidewire,	it	is	inserted	ab	interno	underneath	the	scleral	spur	and	into	the	supraciliary	space	where	it	is	secured	in	place	by	a	series	of	retention	rings.		Once	stabilized	in	the	iridocorneal	angle,	aqueous	may	flow	through	the	stent	and	into	the	suprachoroidal	space	(Figures	1	and	2).8,13	Approved	by	the	FDA	in	August	2016,	it	is	indicated	for	the	treatment	of	mild	to	moderate	primary	open	angle	glaucoma	in	patients	undergoing	concurrent	cataract	surgery.	The	suprachoroidal	space	represents	an	interesting	and	attractive	pathway	for	new	glaucoma	surgical	procedures	as	it	has	the	ability	to	lower	IOP	below	that	of	episcleral	venous	pressure	without	the	formation	of	a	subconjunctival	bleb.14	Under	normal	physiologic	conditions,	the	aqueous	humor	exits	the	anterior	chamber	by	flowing	between	the	ciliary	muscle	bundle	fibers	and	into	the	suprachoroidal	space.15	Once	in	this	space,	it	may	flow	through	the	scleral	connective	tissue	and	into	the	lymphatic	system.14	This	may	best	be	described	as	non-trabecular	flow.		It	has	been	shown	that	a	negative	pressure	gradient	between	the	anterior	chamber	and	the	suprachoroidal	space	drives	this	flow.16	The	ciliary	muscle	represents	the	greatest	resistance	to	aqueous	in	this	pathway,	thus	bypassing	it	may	effectively	lower	IOP.14	Relaxation	of	the	ciliary	muscle	with	atropine	increases	uveoscleral	outflow	while	contraction	with	pilocarpine	reduces	it.17	Intuitively	this	pathway	may	be	seen	as	a	good	target	for	MIGS	devices	as	prostaglandin	analogues	exploit	this	same	route	to	some	degree,	but	rather	than	bypassing	the	ciliary	body	entirely,	they	exhibit	their	effect	by	reducing	extracellular	matrix	components	within	the	ciliary	muscle	so	aqueous	may	pass	more	easily.18	Cyclodialysis	clefts,	whether	iatrogenic	or	traumatic,	have	also	been	shown	to	lower	IOP,	sometimes	to	very	low	levels	with	resulting	posterior	pole	changes.19	When	the	CyPass	Micro-Stent	is	secured	in	the	supraciliary	space,	it	essentially	functions	as	a	permanent	and	controlled	cyclodialysis	cleft,	allowing	aqueous	to	bypass	the	ciliary	body.						 The	purpose	of	this	study	is	to	determine	if	the	CyPass	Micro-Stent	is	a	safe	and	effective	long-term	solution	in	the	treatment	of	glaucoma.		Traditional	surgical	glaucoma	therapies	i.e.,	trabeculectomy	and	shunt	devices	have	failure	rates	of	approximately	47%	
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and	30%	respectively	after	five	years,	along	with	a	high	risk	of	complications	including	blindness.7,20	A	better	long-term	solution	is	needed	without	sacrificing	patient	safety.		To	our	knowledge,	this	will	represent	the	largest	group	of	patients	maintaining	this	length	of	follow	up	(5-8	years)	per	our	search	of	the	PubMed	database.		Additionally,	all	patients	in	this	study	will	have	been	previously	enrolled	in	the	COMPASS	trial,	meaning	that	we	have	true	unmedicated	IOP	data.		Long-term,	effective	solutions	are	needed	for	the	treatment	of	glaucoma,	and	long-term	follow	up	is	lacking	concerning	suprachoroidal	MIGS	devices.		
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Methods:	
	
Study	Design:		Design:	Retrospective	case	control		Treatment	Group:	Patients	with	mild	to	moderate	POAG	implanted	with	the	CyPass	Micro-Stent	in	conjunction	with	cataract	surgery	Control	Group:	Patients	with	mild	to	moderate	POAG	that	underwent	cataract	surgery	alone	Follow	up	Period:	Approximately	5-8	years	(1794-3131	days)	Number	of	Subjects	Planned/Analyzed:	-33	eyes	of	33	patients	in	treatment	group	-12	eyes	of	12	patients	in	control	group	
Primary	Outcome	Measure:	Complete	success	is	defined	as	an	IOP	≤	18 mmHg	without	a	need	for	postoperative	medication	and/or	any	secondary	procedure	needed	to	control	IOP.			Qualified	success	is	defined	as	an	IOP	≤	18 mmHg	with	no	more	than	1	postoperative	medication	and/or	laser	trabeculoplasty	to	control	IOP		Failure	defined	as	an	IOP	>	18	mmHg,	more	than	1	medication	needed	to	control	IOP,	or	incisional	surgery	needed	to	control	IOP	
	
Secondary	Outcome	Measures:	Change	in	mean	anti-glaucoma	medications	between	groups	Change	in	mean	IOP	between	groups	Change	in	visual	field	mean	deviation	scores	between	groups		Safety	data	collected	in	the	form	of	loss	of	best-corrected	visual	acuity	(BCVA),	IOP	changes,	slit	lamp	and	fundus	abnormalities,	and	adverse	events.	
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Study	Subjects:	The	study	protocol	was	approved	by	the	NOVA	Southeastern	University	institutional	review	board	and	conformed	to	both	the	Declaration	of	Helsinki	tenets	and	the	Health	Insurance	Portability	and	Accountability	Act	regulations.	All	patients	included	in	analysis	were	part	of	the	COMPASS	FDA	approved	clinical	trial	and	had	since	exited	the	study.		Data	concerning	33	eyes	of	33	patients	in	the	treatment	arm	(CyPass	combined	with	phacoemulsification)	and	12	eyes	of	12	patients	in	the	control	arm	(Phacoemulsification	alone)	were	reviewed	by	research	coordinators	and	investigators	for	study	inclusion.		Below	are	subject	inclusion/exclusion	criteria	as	worded	from	the	COMPASS	trial.	
Subject	Inclusion	Criteria	(COMPASS	Trial)	Individuals	will	be	assessed	for	study	eligibility	based	on	the	criteria	presented	below.	Ocular	criteria	relates	to	the	study	eye	only.	1. Individuals	45	years	of	age	or	older,	male	or	female.	2. A	diagnosis	of	primary	open	angle	glaucoma	(POAG).	3. At	the	Screening	Visit,	a	mean	(or	median)	medicated	IOP	of	≤	25	mmHg	or	an	
unmedicated	IOP	of	≥	21	mmHg	and	≤	33	mmHg.	4. At	the	Baseline	Visit,	a	mean	unmedicated	IOP	of	≥	21mmHg	and	≤33	mmHg.	The	mean	will	be	derived	from	the	diurnal	IOP	reading	taken	over	the	course	of	the	Baseline	Visit	day.		Additionally,	the	baseline	mean	unmedicated	diurnal	IOP	
must	be	≥	3	mmHg	higher	than	the	mediated	IOP	measured	in	the	Screening	
Visit.	5. Diagnosis	of	glaucoma	within	90	days	prior	to	the	Screening	Visit	substantiated	using	the	ophthalmoscopy	and	visual	field	testing	with	the	Humphrey	automated	perimeter	using	the	SITA	Standard	24-2	testing	algorithm.	Mean	deviation	score	must	be	≥-12.0	dB	and	<	0	dB.	
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a. For	subjects	without	a	previously	document	history	of	glaucoma,	Humphrey	24-2	SITA	Standard	visual	field	testing	confirming	diagnosis	of	glaucoma	must	be	performed	at	least	twice	by	the	time	of	the	Baseline	Visit.	b. For	subjects	who	have	utilized	ocular	hypotensive	medications	for	≥	3	months	prior	to	the	Screening	Visit	but	who	have	visual	field	mean	deviation	scores	≥	0	dB,	nerve	findings	characteristic	of	glaucoma	must	be	documented.	Any	of	the	following	optic	disc	and	nerve	fiber	layer	findings	are	considered	characteristic	of	glaucoma:	i. Cupping	with	increased	vertical	cup-to-disc	ratio	ii. Nerve	fiber	layer	loss	consistent	with	glaucoma	iii. Segmental	loss	of	neuroretinal	rim	(notching	of	the	rim)	iv. Presence	of	a	splinter	disc	hemorrhage	Optical	scanning	lasers	may	be	used	to	document	and	support	the	presence	of	glaucomatous	optic	nerve	changes,	but	may	not	be	considered	as	a	substitute	for	ophthalmoscopy	for	the	purpose	of	establishing	glaucoma	diagnosis.	Acceptable	optical	scanning	laser	diagnostics	include:	
§ Heidelberg	Retina	Tomography	(HRT):	abnormal	nerve	fiber	layer	(NFL)	findings	indicated	by	a	yellow	exclamation	mark	and/or	a	red	x.	
§ Zeiss/Humphrey	Glaucoma	Diagnostic	Unit	(GDx):	abnormal	NFL	findings	with	a	Nerve	Fiber	Index	(NFI)	reading	of	>	31	and/or	<	5%	p-value	indicator	for	NFL.	
§ Optical	Coherency	Testing	(OCT):	abnormal	NFL	findings	in	the	red	or	yellow	areas,	below	the	area	of	normal	on	the	Analysis	of	Thickness.	6. Gonioscopy	confirming	normal	angle	anatomy	at	the	site	of	implantation.	7. Shaffer	grade	of	≥	III	in	all	four	quadrants.	8. An	operable	age-related	cataract	with	BCVA	of	20/40	or	worse,	eligible	for	phacoemulsification.	(If	the	BCVA	is	better	than	20/40,	testing	with	a	Brightness	Acuity	Meter	(BAT)	on	a	medium	setting	must	result	in	a	BCVA	of	20/40	or	worse.)	
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Subject	Exclusion	Criteria	(COMPASS	Trial)	Excluded	from	the	study	will	be	individuals	with	the	following	characteristics.	Unless	specified	otherwise,	all	ocular	criteria	refer	to	the	study	eye	only.	1. Inability	to	complete	a	reliable	24-2	SITA	Standard	Humphrey	visual	field	on	the	study	eye	at	screening	(fixation	losses,	false	positive	errors	and	false	negative	errors	should	not	be	greater	than	30%).	2. Use	of	more	than	3	ocular	hypotensive	medications.	(Combination	medications	count	as	2	medications.)	3. Use	of	oral	hypotensive	medication	treatment	for	glaucoma	in	the	fellow	eye.	4. Significant	risk	by	a	washout	of	medication	including	those	subjects	with	advanced	glaucoma	evidenced	by	an	afferent	pupillary	defect,	a	C:	D	ratio	≥	0.9	or	encroachment	of	field	loss	within	the	central	5	degrees	as	indicated	by	≥	2	depressed	points	of	0.5%	probability	on	the	24-2	SITA	Standard	Humphrey	visual	field.	5. Previous	glaucoma	procedure	with	or	without	an	implantable	glaucoma	device	(with	exception	of	laser	treatments	to	the	trabecular	meshwork	such	as	a	Laser	Trabeculoplasty	performed	more	than	three	months	prior	to	study	enrollment.)	6. History	of	elevated	intraocular	pressure	due	to	steroid	response.	7. Proliferative	diabetic	retinopathy.	8. Previous	surgery	for	retinal	detachment.	9. Central	corneal	thickness	>	620	microns.	10. Clinically	significant	corneal	dystrophy.	11. Previous	corneal	surgery.	12. Wet	age-related	macular	degeneration.	13. Clinically	significant	ocular	pathology,	other	than	cataract	and	glaucoma.	14. Diagnosis	of	acute	angle	closure,	traumatic,	congenital,	malignant,	uveitic,	pseudoexfoliative,	pigmentary	or	neovascular	glaucoma.	15. Best	corrected	visual	acuity	worse	than	20/80	in	the	fellow	eye.	
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16. Clinically	significant	ocular	inflammation	or	infection	within	thirty	days	prior	to	screening.	17. Uncontrolled	systemic	disease	that	in	the	opinion	of	the	Investigator	would	put	the	subject's	health	at	risk	and/or	prevent	the	subject	from	completing	all	study	visits.	18. Pregnant	or	nursing	females.	
Subject	Inclusion	Criteria	(Current	Study)	1. Both	male	and	female	subjects	with	no	preference	given	to	either	gender.		2. Must	have	been	previously	enrolled	in	COMPASS	trial	and	returned	to	general		 clinic.		
Subject	Exclusion	Criteria	(Current	Study)	1. History	of	corneal	refractive	surgery	since	exiting	COMPASS	trial,	i.e.	LASIK	2. Wet-Age	macular	degeneration	requiring	Anti-VEGF	injections	3. Pregnant	or	nursing	females	4. Other	surgical	intervention	not	for	the	purpose	of	IOP	control	that	may	have	long	term	impact	on	IOP,	i.e.	retinal	detachment	repair	5. Development	of	secondary	type	glaucoma,	i.e.	neovascular	glaucoma		
Surgical	Technique	Using	a	clear	corneal	temporal	approach,	a	paracentesis	site	was	made	and	the	anterior	chamber	filled	with	viscoelastic.		A	2.4	mm	incision	was	made	using	a	keratome.	Following	phacoemulsification	and	removal	of	the	lens,	a	posterior	chamber	IOL	was	placed	into	the	capsular	bag.		Following	successful	cataract	surgery,	the	microstent	was	loaded	onto	the	guidewire	of	the	applier	(Figure	3).		Under	direct	gonioscopy,	the	microstent	was	implanted	through	blunt	dissection	between	the	plane	of	the	ciliary	body	and	sclera	using	the	guidewire	tip.	Once	secured	in	place,	the	applier	was	withdrawn	from	the	eye	and	viscoelastic	evacuated.13			
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Statistical	Methods:	Statistical	analysis	performed	with	support	of,	Patrick	Hardigan,	Ph.D.,	Professor	of	Public	Health	Dr.	Kiran	C.	Patel	College	of	Osteopathic	Medicine	Associate	Dean	of	Academic	Affairs	Health	Professions	Division	Nova	Southeastern	University	Ft.	Lauderdale,	Fl	33328		 Descriptive	statistics	were	calculated	for	all	study	variables.	This	included	the	mean	and	standard	deviation	for	continuous	measures,	counts	and	frequencies	for	categorical	measures.	R	3.2.2	was	used	for	all	statistical	analysis	and	statistical	significance	was	found	at	p	<	0.05.	For	the	primary	outcome	measure,	a	bivariate	analysis	using	a	Fisher’s	exact	test	was	first	conducted	to	investigate	group	differences	in	the	proportion	of	patients	with	“complete	success”	defined	as	an	IOP	≤	18 mmHg	without	need	for	postoperative	medication,	laser	trabeculoplasty,	or	incisional	surgery,	“qualified	success”	defined	as	an	IOP	≤	18 mmHg	with	no	more	than	1	postoperative	medication	and/or	laser	trabeculoplasty	needed	to	control	IOP,	and	“failures”	defined	as	individuals	with	IOP	>18 mmHg	and/or	individuals	with	more	than	1	postoperative	medication,	and/or	individuals	who	subsequently	underwent	a	secondary	incisional	ocular	procedure	to	control	IOP.	We	then	dichotomized	the	dependent	variable	into	two	measures:	Success	vs.	Other	(Qualified	or	Failure)	and	created	a	logistic	regression	model	containing	group	(CyPass	vs.	Other),	age,	gender,	preoperative	visual	field	mean	deviation,	preoperative	washout	IOP,	and	preoperative	anti-glaucoma	medication	usage.	For	continuous	measures	we	first	conducted	bivariate	analyses	across	the	following	measures	to	see	if	we	had	comparable	groups:	Age,	preoperative	visual	field	mean	deviation,	postoperative	visual	field	mean	deviation,	preoperative	IOP,	preoperative	washout	IOP,	postoperative	IOP,	preoperative	anti-glaucoma	medications,	postoperative	anti-glaucoma	medications,	and	follow	up	period	since	surgery.	For	this	analysis	we	used	a	Wilcoxon-Mann-Whitney	test.	We	then	created	difference	scores	for	the	variables	visual	field,	intraocular	pressure	and	medication	use	and	compared	group	differences	using	a	Wilcoxon-Mann-Whitney	test.	Lastly,	we	created	linear	models	to	look	for	changes	in	visual	field,	intraocular	
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pressure	and	medication	use.	The	dependent	variable	in	all	models	was	the	change	measure,	and	the	independent	variables	were	treatment	group	(CyPass	vs.	Other),	age	and	gender.	As	medication	use	was	a	count	variable	we	used	a	negative	binomial	distribution	to	analyze	this	change.	Patients	undergoing	secondary	incisional	ocular	procedures	to	control	IOP	were	treated	as	non-responders.		For	these	patients	mean	diurnal	washout	IOP	at	baseline	was	imputed	as	the	mean	postoperative	IOP.		The	same	method	was	used	for	medications,	with	the	baseline	preoperative	medication	use	imputed	for	postoperative	medication	usage.		Please	refer	to	Table	1	for	patient	baseline,	preoperative,	and	postoperative	data.							
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Results:	
	 		 Twenty	eyes	in	the	CyPass	group	were	categorized	as	complete	success	versus	2	eyes	in	the	control	group.	Nine	patients	were	classified	as	qualified	success	in	the	microstent	group	based	on	the	following;	5	for	medication	usage,	2	for	laser	trabeculoplasty,	and	2	requiring	both	modalities.		Five	patients	were	classified	as	qualified	success	in	the	control	group	based	on	the	following;	4	for	medication	usage	and	1	for	laser	trabeculoplasty.		Four	patients	were	classified	as	“failures”	in	the	microstent	group	based	on	the	following:	1	for	medication	usage,	1	for	IOP,	1	for	both	IOP	and	medication	usage,	and	1	for	IOP	and	secondary	incisional	surgery.		Five	patients	were	classified	as	“failures”	in	the	control	group	based	on	the	following:	1	for	medication	usage,	1	for	IOP,	and	3	for	secondary	incisional	surgery.	Summarized	data	may	be	found	in	Table	3.			Results	from	the	bivariate	Fisher’s	Exact	test	indicate	that	significantly	more	subjects	in	the	CyPass	group	(61%)	experienced	complete	success	than	the	control	group	(17%)	(p	<	0.05)	(Table	2).		Results	of	the	binary	logistic	regression	model	indicate	that	there	was	a	significant	difference	between	the	CyPass	and	control	groups	when	controlling	for	preoperative	baseline	parameters	(χ2(6)	=	19.045,	p	=	0.004).	The	odds	ratio	for	the	group	coefficient	is	9.02	with	a	95%	confidence	interval	of	[1.69,75.78].	This	suggests	that	controlling	for	the	effects	of	age,	sex,	preoperative	visual	fields,	preoperative	IOP,	and	preoperative	anti-glaucoma	medication	usage,	individuals	in	the	control	group	are	9	times	more	likely	to	have	a	failed	surgery	than	those	in	the	CyPass	group.	Mean	postoperative	IOP	was	17.7±4.8	in	the	control	group	versus	15.0±4.4	in	the	treatment	group	(p=0.08),	while	mean	medication	usage	was	0.9±0.7	in	the	control	group	versus	0.4±0.7	in	the	treatment	group	(p=0.01).		Figures	5	and	6	show	pre	and	postoperative	medication	usage	and	IOP	respectively.		Average	follow	up	was	2298±433	days	for	the	treatment	group,	and	2419.3±469	for	the	control	group	(p=0.43).						
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Discussion:		
The COMPASS trial was the pivotal FDA clinical trial that endorsed the approval of the 
CyPass in the United States.13 It was a 2-year randomized trial with over 500 patients involved, 
and represented the largest interventional MIGS trial to date.  Three hundred seventy-four 
patients received the CyPass device.  The study compared the efficacy and safety of patients 
with POAG undergoing CyPass implantation in conjunction with cataract surgery versus those 
undergoing cataract surgery alone.  Our center enrolled 88 patients in the trial, 64 in the 
treatment group and 24 in the control group (Figure 4, Site 05).  The 45 patients in the current 
trial represent a long-term follow up subgroup that had exited the study and returned to general 
clinic.  Our findings demonstrate that the CyPass Micro-Stent has good long-term effectiveness 
in the treatment of mild-moderate POAG when combined with cataract surgery.  A significantly 
higher percentage of eyes in the CyPass group (61%) versus control (17%) maintained an IOP 
of ≤ 18 mmHg without the need for medical therapy, laser trabeculoplasty, or incisional 
surgical intervention (p < 0.05) (Table 2).  No patient had an IOP of lower than 6, and there 
were no incidences of hypotony maculopathy or corneal decompensation.  By comparison, the 
COMPASS trial demonstrated 65% of all microstented subjects maintaining washout IOP of 
between 6 and 18 mmHg inclusive at 24 months in per-protocol (PP) analysis vs. 44% in 
control group.13 In intention-to-treat (ITT) analysis the 24-month proportion of COMPASS 
patients achieving an IOP level of 6 to 18 mmHg were 61% in microstented subjects vs. 44 % 
in control group (P<0.001).13 The results of the current study are nearly equivalent to that of 
microstented subjects in COMPASS, and demonstrate that patients continued to maintain a 
good level of IOP control after a 24-month period with significantly longer follow up in the 
current study, compared with control patients having poorer IOP control, more medication 
usage, and incisional surgical intervention over the same time period of time.  Patients in the 
current study also required less ocular hypotensive medications than control, 0.4 ± 0.7 vs. 0.9 ± 
0.7 respectively (p=0.01) (Figure 5).  Comparatively microstented patients in COMPASS 
required 0.2 ± 0.6 medications vs. 0.6 ± 0.8 in control group.13 Although not statistically 
significant, there was a clear trend when comparing IOP reduction at medicated baseline vs. 
last follow up in the current study, with the microstent group obtaining a reduction of 17.7 ± 
3.3 to 15.0 ± 4.4 (15% reduction) vs. 18.6 ± 4.4 to 17.7 ± 4.8 in control group (5% reduction) 
(p=0.08) (Figure 6).  When evaluating the subset of patients that were classified as “complete 
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success” in the CyPass group (20 of 33 eyes), and comparing washout IOP at baseline to 
postoperative IOP, patients had a reduction in IOP from a mean of 23.75 ± 1.75 mmHg to 
14.30 ± 2.89 (40% reduction) (p<0.001) at an average follow up of 6.27 years.  Preoperatively 
this group went from 1.35 ± 0.93 medications to zero at follow up. 
 One of 33 (3%) eyes underwent secondary incisional surgical intervention (trabecular 
outflow procedure) in the CyPass group versus 3 of 12 eyes (25%) in the control group, with 2 
eyes undergoing a trabecular outflow type procedure and 1 eye requiring a trabeculectomy.  
There was no progression in visual fields in either group (p=0.93).  This finding is somewhat 
surprising given that patients in the control group had a trend toward higher IOP levels, 
however the control group still maintained a mean IOP of under 18 mmHg (17.7 ± 4.8), albeit 
at the expense of higher medication usage and more surgical intervention needed to achieve 
this goal.  It is possible that changes in visual field loss between groups would manifest over a 
longer follow up period.  Furthermore, there is often a discrepancy between functional and 
structural changes in glaucoma, and many patients may show progressive structural changes in 
the absence of changes on automated visual field testing21.  As long-term nerve fiber layer data 
was not collected, we are unable to be certain if there were changes in this parameter. 
           The CyPass Microstent compares favorably to other MIGS procedures/devices, however 
caution must be exercised when comparing trial results secondary to different methodologies 
used as well as different inclusion/exclusion criteria.  The iStent trabecular micro-bypass 
device is implanted through the trabecular meshwork to target Schlemm’s canal and enhance 
trabecular outflow.22  At the 24-month time point 61% of patients in the stent group achieved 
an unmedicated IOP of ≤	21 mmHg, compared with 61% in the current trial meeting the more 
stringent criterion of ≤	18	mmHg.23		Furthermore,	the	difference	in	the	anti-glaucoma	medication	usage	between	the	stent	group	and	control	group	had	dissipated	by	the	24	month	mark,	while	it	remained	clinically	significant	in	the	current	trial	at	a	mean	of	over	6	years.		The HORIZON trial was a randomized clinical trial comparing another trabecular 
device, the Hydrus Microstent, (Ivantis Inc, Irvine, CA), in combination with 
phacoemulsification.  At 24 months the microstent group demonstrated a 7.6 reduction in mean 
IOP versus baseline versus 9.5 mmHg at over 5 years in the current trial when considering 
unmedicated patients, demonstrating approximately a 2-point benefit in IOP reduction for the 
CyPass Micro-Stent. Although the XEN gel stent may be considered a MIGS procedure, it is 
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indicated for more severe refractory glaucoma in which prior surgery or medications have 
failed, rather than mild-moderate glaucoma.24  Made of a porcine gelatin material, it is 
implanted ab interno and creates a conduit from the anterior chamber into the subconjunctival 
space to allow for aqueous outflow.24  Studies of the current Xen model have demonstrated an 
IOP lowering effect from 29% to 45% with anywhere from 39% to 90% of patients medication 
free postoperatively.25  This is in line with the current study in which there was a 39% drop in 
IOP along with 61% of patients being medication free postoperatively.  Additionally, there is no 
chance of conjunctival fibrosis following implantation of the CyPass Micro-Stent as there is 
with the Xen implant, leaving room for future filtering surgery if needed.  
  Glaucoma surgery must not only be efficacious but demonstrate adequate safety over a 
period of time.  This is especially true for MIGS procedures, as they are utilized earlier in the 
disease process.  One of many safety parameters measured during FDA clinical trials involving 
MIGS procedures is endothelial cell loss (ECL). At the time of this writing (early September 
2018), Alcon globally withdrew the CyPass Micro-Stent based on concerns of progressive ECL 
shown in the COMPASS-XT trial.  Performed at the request of the FDA, the COMPASS-XT 
trial was a 3-year extension of the 2-year COMPASS trial and included 282 of the 505 patients 
enrolled in the COMPASS trial, with 253 patients completing the 60-month visit.  At the end of 
the 24-month COMPASS trial, the treatment and control group demonstrated similar mean and 
percentage of eyes with > 30% ECL.  However, by the 60-month follow up visit, the CyPass 
group had shown a significantly higher mean and percentage of eyes with ECL (Figures 7 and 
8, data available at (www.alcon.com/cypass).  The only variable found to be correlated with 
progressive ECL was device positioning (Figure 9).  Based on this data, it seems as though the 
ideal position of the device is with no retention rings visible, with the anterior position of the 
device at or below the trabecular meshwork.  When positioned in this manner, an ECL of 
1.39% per year occurred, which is more in line with what is expected for patients with 
glaucoma, although this is still higher than control group loss of 0.36% per year.26  During the 
clinical trial, surgeons were instructed to implant the device with an optimal position of 1 ring 
visible, which is reflected in FDA “directions for use” (DFU).  Only 1 patient developed mild 
corneal edema at 51 months during COMPASS-XT, and this was successfully resolved with 
device trimming a subsequent resolution of edema.  The CyPass Micro-Stent compares 
favorably with ECL after traditional glaucoma surgery, with tube shunts demonstrating up to 
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24.6% reduction in mean ECL at 4 years, and trabeculectomy up to 28% at 1 year.27,28  
Compared with other MIGS procedures, the CyPass has shown greater ECL although the 
follow period in other trials has not been as long.  In example, the Hydrus Microstent exhibited 
14% mean ECL at 2 years versus 18.4 % for CyPass at 5 years.  Our group is currently working 
on a trial to reexamine all original COMPASS patients from our site and revaluate stent 
positioning and ECL.      														A	major	strength	of	this	study	is	the	significant	length	of	follow	up.		To	our	knowledge	it	represents	the	longest	follow	up	data	available	on	the	CyPass	Micro-Stent	and	of	all	MIGS	procedures	in	general.		Furthermore,	this	subset	of	patients	was	part	of	the	COMPASS	study	meaning	we	have	valuable	baseline	data	from	a	randomized	clinical	trial.		This	data	clearly	demonstrates	the	sustained	efficacy	of	the	CyPass	Micro-Stent	in	terms	of	IOP	lowering	capability.	There	are	several	weaknesses	to	this	study.		This	was	a	retrospective	chart	review	and	not	a	randomized	controlled	clinical	trial.	Medication	reintroduction	was	not	strictly	controlled	once	patients	were	returned	to	general	clinic,	and	there	was	no	postoperative	washout	IOP	in	all	patients,	making	it	difficult	to	compare	our	results	with	other	trials	that	have	this	parameter.		The	IOP	used	for	analysis	at	follow	up	only	represents	one	time	point,	and	there	was	likely	some	IOP	fluctuation	post	surgically.		This	limits	our	ability	to	determine	IOP	change	over	time	to	some	degree.	Some	patients	underwent	secondary	surgical	procedures	for	IOP	control,	which	confounds	our	true	ability	to	determine	true	postoperative	IOP	and	medication	usage	in	that	subset	of	patients.		All	patients	underwent	concurrent	cataract	surgery,	which	has	also	been	shown	to	affect	IOP	with	a	significant	lowering	effect.29,30	Despite	these	drawbacks,	this	study	provides	quality	long-term	data	for	this	MIGS	device. 			
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Conclusion 
 In conclusion, the CyPass Micro-Stent combined with cataract surgery demonstrates 
good long-term efficacy over cataract surgery alone in patients with mild-moderate POAG.  
Further study is needed to determine the long-term safety of the procedure.
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Tables	and	Figures:	
	
	
				
		Figure	1:	CyPass	within	supraciliary	space,	increasing	non-trabecular	flow	(Hoeh,	H)	
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		Figure	2:	CyPass	Micro-Stent	in	situ.	(Photo	by	Mike	McFarland,	OD)		
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Figure	3:	CyPass	Micro-Stent	on	guidewire	with	visible	fenestrations.	Blunt	guidewire	at	distal	end	facilitates	dissection	of	plane	between	ciliary	body	and	sclera	(Vold,	SD)						
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		Figure	4:	COMPASS	enrollment	by	site.	Current	study	subjects	a	long-term	subgroup	of	site	05											
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Figure	5.	Medication	usage	by	treatment	group	
				Figure	6.	IOP	by	treatment	group	
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	Figure	7.	Mean	change	in	ECD	from	baseline	(Data	provided	by	Alcon)					
	Figure	8.	Percentage	of	patients	>	30%	ECL	from	baseline	(Data	provided	by	Alcon)									
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		Figure	9:	Annual	ECL	based	on	stent	positioning			
Table	1.	Baseline,	preoperative,	and	postoperative	data	 		
Parameter	 CyPass	 Control	 P-Value	N	(eyes)	 33	 12	 −	Female	Count	(Percent)	 19	(57.6)	 14	(42.4)	 −	Right	Eyes	Count	(Percent)	 16	(48.5)	 8	(66.7)	 −	Mean	Age	±	SD	 66.8	±	7.3	 65.9	±	5.5	 0.53	Mean	Pre	VF	±	SD	 -3.1	±	2.3	 -3.3	±	2.5	 0.73	Mean	Post	VF	±	SD	 -3.7	±	2.7	 -3.6	±	2.2	 0.93	Mean	Pre	IOP	WO	±	SD	 24.4	±	2.6	 24.1	±	2.4	 0.61	Mean	Pre	IOP	±	SD	 17.7	±	3.3	 18.6	±	4.4	 0.76	Mean	Post	IOP	±	SD	 15.0	±	4.4	 17.7	±	4.8	 0.08	Mean	Pre	Med	±	SD	 1.5	±	1.0	 1.3	±	1.0	 0.58	Mean	Post	Med	±	SD	 0.4	±	0.7	 0.9	±	0.7	 0.01*	Mean	Days	PO	±	SD	 2298.1	±	433	 2419.3	±	469.2	 0.43	Pre	VF=preoperative	Humphrey	mean	deviation;	Post	VF=postoperative	Humphrey	mean	deviation;	Pre	IOP	WO=preoperative	washout	IOP	found	in	COMPASS	trial;	Pre	IOP=	preoperative	intraocular	pressure	at	COMPASS	screening;	Post	IOP=	postoperative	intraocular	pressure	at	last	clinic	exam;	Pre	Med=	preoperative	glaucoma	medication	usage	at	COMPASS	screening;	Post	Med=	postoperative	glaucoma	medication	usage	at	last	clinic	exam;	Days	PO=	days	since	surgery;*P<0.05					 		
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Table 2. Success, Qualified 
Success, and Failure 
CyPass 
Count 
(Percent) 
Control 
Count 
(Percent) 
P-Value 
Complete Success  20 (60.6) 2 (16.7) 0.008 
Qualified Success 9 (27.3) 5 (41.7)  
Failure 4 (24.2) 5 (41.7)  				
Table	3.	Reasons	for	
“Qualified	Success”	or	
“Failure”.	 Qualified	 Failure	SLT	 Med	 Mult	 IOP	 Med	 Sx	 Mult	
CyPass	 2	 5	 2	 1	 1	 0	 2	
Control	 1	 4	 0	 1	 1	 3	 0	SLT=selective	laser	trabeculoplasty;	Med=medication;	Multi=combination;	IOP=intraocular	pressure;	Sx=incisional	surgical	intervention		
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Raw	Data		
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